These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3882141)

  • 21. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation].
    Matsushita T; Akatsuka Y; Towatari M; Takeyama K; Miyamura K; Sugihara T; Minami S; Kodera Y
    Rinsho Ketsueki; 1989 Apr; 30(4):429-36. PubMed ID: 2671437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months.
    Yee GC; McGuire TR; St Pierre BA; Self SG; Zager RA; Sullivan KM; Deeg HJ
    Bone Marrow Transplant; 1989 Nov; 4(6):691-4. PubMed ID: 2684309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation.
    Yee GC; Self SG; McGuire TR; Carlin J; Sanders JE; Deeg HJ
    N Engl J Med; 1988 Jul; 319(2):65-70. PubMed ID: 3288872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.
    Deeg HJ; Spitzer TR; Cottler-Fox M; Cahill R; Pickle LW
    Bone Marrow Transplant; 1991 Mar; 7(3):193-8. PubMed ID: 2059756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors.
    Nawa Y; Hara M; Tanimoto K; Nakase K; Kozuka T; Maeda Y
    Int J Hematol; 2006 Feb; 83(2):159-63. PubMed ID: 16513536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract]   [Full Text] [Related]  

  • 28. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates.
    Deeg HJ; Storb R; Appelbaum FR; Kennedy MS; Graham TC; Thomas ED
    Transplantation; 1984 Jan; 37(1):62-5. PubMed ID: 6364490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy.
    Champlin RE; Ho WG; Nimer SD; Gajewski JG; Selch M; Burnison M; Holley G; Yam P; Petz L; Winston DJ
    Transplantation; 1990 Apr; 49(4):720-4. PubMed ID: 2326866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
    Filipovich AH; Krawczak CL; Kersey JH; McGlave P; Ramsay NK; Goldman A; Goldstein G
    Br J Haematol; 1985 May; 60(1):143-52. PubMed ID: 3890926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation.
    Stockschlaeder M; Storb R; Pepe M; Longton G; McDonald G; Anasetti C; Appelbaum F; Doney K; Martin P; Sullivan K
    Br J Haematol; 1992 Jan; 80(1):49-54. PubMed ID: 1536809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival.
    Doney K; Fisher LD; Appelbaum FR; Buckner CD; Storb R; Singer J; Fefer A; Anasetti C; Beatty P; Bensinger W
    Bone Marrow Transplant; 1991 Jun; 7(6):453-9. PubMed ID: 1873592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marrow transplant experience for children with severe aplastic anemia.
    Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
    Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.